-
Mashup Score: 0Global Hemophilia Survey: Patient Experiences & Needs - 30 day(s) ago
Sanofi’s global hemophilia survey assessed the needs, experiences, & attitudes of 2,700 patients, caregivers, & hematologists in 11 countries.
Source: www.sanofi.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1US - 2 month(s) ago
In the United States we’re partnering with the Thurgood Marshall College Fund and Rutgers University Ernest Mario School of Pharmacy to foster a diverse and inclusive STEM community for students from underrepresented ethnic backgrounds. “Representation in healthcare is vital to ensure diverse perspectives, experiences, and needs are acknowledged and addressed, ultimately leading to more inclusive, accessible, and effective healthcare for all. “” Fostering diversity and representation in the healthcare
Source: www.sanofi.comCategories: General Medicine News, PayerTweet-
This #WomensHistoryMonth, in partnership with @RutgersU, we’re spotlighting our Sanofi NextGen Scholar Anabell Castillo who is driven to help pave the way for underrepresented voices in healthcare. Learn More: https://t.co/kuy1gv2tyd #AMillionConversations https://t.co/aehKxt3xTT
-
-
Mashup Score: 1US - 2 month(s) ago
In the United States we’re partnering with the Thurgood Marshall College Fund and Rutgers University Ernest Mario School of Pharmacy to foster a diverse and inclusive STEM community for students from underrepresented ethnic backgrounds. “Representation in healthcare is vital to ensure diverse perspectives, experiences, and needs are acknowledged and addressed, ultimately leading to more inclusive, accessible, and effective healthcare for all. “” Fostering diversity and representation in the healthcare
Source: www.sanofi.comCategories: General Medicine News, PayerTweet-
As a Sanofi NextGen scholar, Ifeoma is committed to creating a more inclusive healthcare system. Learn how we're supporting our next generation of healthcare leaders, like Ifeoma: https://t.co/jFDRDwBg11 #AMillionConversations https://t.co/JezHgSxPwz
-
-
Mashup Score: 47
Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant Sarclisa added to bortezomib,…
Source: www.sanofi.comCategories: General Medicine News, Hem/OncsTweet-
A timely great news before the start of #ASH23 isatuximab: Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant @TheIACH @SanofiFR @sanofi https://t.co/kHiIbKVzRm
-
-
Mashup Score: 47
Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant Sarclisa added to bortezomib,…
Source: www.sanofi.comCategories: General Medicine News, Hem/OncsTweet-
A timely great news before the start of #ASH23 isatuximab: Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant @TheIACH @SanofiFR @sanofi https://t.co/kHiIbKVzRm
-
-
Mashup Score: 4
Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo First and only biologic to show rapid and significant improvement in lung function (160 mL in FEV1) compared to…
Source: www.sanofi.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Love seeing these positive results for a drug being repurposed for #COPD! But we can’t just do this for on-patent drugs… we need to unlock the full potential of every @US_FDA approved drug to treat every disease possible! https://t.co/CCMHCAeDBK Join our mission @EveryCure !
-
-
Mashup Score: 0
Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance Paris, March 16, 2023. Sanofi announces that it will cut the list price of Lantus (insulin glargine injection) 100 Units/mL, its most widely prescribed insulin in the U.S., by 78 percent. The company also will establish a $35 cap on…
Source: www.sanofi.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Sanofi has already a Lantus authorized generic at 70% discount to Lantus launched last year. Let the price drops due to competition begin! It’s good for patients. Read Sanofi press release: @sanofi https://t.co/AmcO3IifXm
-
-
Mashup Score: 0
Sanofi announces change in R&D leadership Paris, February 13, 2023. Sanofi announced today that Dr. John Reed, its Global Head of R&D, will be leaving the company to pursue a new opportunity outside Sanofi. The company warmly thanks Dr. Reed for his leadership over these last years. Since joining Sanofi in 2018, John has laid the foundation for the company’s R&D transformation. He helped…
Source: www.sanofi.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Sanofi R&D head leaves in surprise departure https://t.co/a8rDRHl34T
-
-
Mashup Score: 3Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants - Sanofi - 2 year(s) ago
European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants Beyfortus is the first and only broadly protective option against RSV for newborns and infantsResults from the clinical development program reinforce Beyfortus’ consistency in reducing RSV infections requiring medical care, including hospitalizations Paris, November 4, 2022….
Source: www.sanofi.comCategories: Expert Picks, Latest HeadlinesTweet-
Happy that long-acting antibody to protect newborns and infants from RSV this particularly severe season is coming to US and approved in Europe - made by Sanofi and Aztrazeneca- monoclonal antibody- Phase 3 MELODY trial published spring 2022- details here https://t.co/957W9NWbU9
-
-
Mashup Score: 0When Cancer Grows Old - Sanofi - 2 year(s) ago
Our When Cancer Grows Old™ initiative addresses the challenges of cancer and aging
Source: www.sanofi.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Dr Extermann highlighting the @sanofi report “When Cancer Grows old” #gerionc @SIOGorg https://t.co/gH586zGGlV
-
The answer? All three are major concerns for those living with hemophilia. Discover the full list and more insights from our survey with @HarrisPoll: https://t.co/gdl0uwTSVr #WorldHemophiliaDay